Popular Articles
Cellulite Treatment

POZEN Submits New Drug Application For VIMOVO™ (PN 400)
POZEN Inc. (NASDAQ:POZN), announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for the marketing approval of VIMOVO™ (PN 400), the combination of enteric coated (EC) naproxen and immediate release esomeprazole. POZEN and AstraZeneca entered into a global co-development agreement for VIMOVO in August 2006. Pending regulatory approval, the proposed trade name is VIMOVO and the proposed indications are for the signs and symptoms of osteoarthritis, rheumatoid arthritis and ankylosing spondylitis in patients who are at risk for developing NSAID-associated ulcers.
generic viagra online
This Time Around, Debate Much Different
Insurance companies, "the industry that gets credit for helping to kill the Clinton administration"s health care overhaul 15 years ago," are now "striking a conciliatory tone as it faces the most serious attempt to overhaul the system since that effort collapsed," CQ Politics reports. With low favorability ratings and Democrats in control of the federal government, "insurers know they aren"t in a good bargaining position" this time around. They have already offered concessions, including providing "insurance in the individual markets to everyone, without regard to who is sick," and not "charging people who are ill higher rates and cut health care costs." But they"ve also been ""careful to structure their offers in such a way that appears significant but does not overpromise." An individual mandate for all Americans and an end to health screening for applicants could offer "a win-win outcome, one that will benefit not just patients but potentially the profits of the industry as well." But "perhaps the biggest motivation for insurers to deal now is that they fear what might happen if they don"t" - the "creation of a government-run plan that would be more attractive to the public and siphon off customers" (Adams, 6/1).
News of the day
MUHC Researcher Awarded $500,000 To Study Pathogenesis Of Infectious Disease
The Burroughs Wellcome Fund (BWF) has announced the recipients of the 2009 Investigators in the Pathogenesis of Infectious Disease Award. MUHC researcher Dr. Maya Saleh was one of six recipients granted $500,000 over a 6-year period for her research proposal, "Regulation and molecular mechanisms of NLR-mediated innate immunity."
Public Health

Heating Heart With Catheter Better Than Drugs For Common Heart Rhythm Disorder

Treating a common heart rhythm disorder by burning heart tissue with a catheter works dramatically better than drug treatments, a major international study has found. One year after undergoing a treatment called catheter ablation, 63 percent of patients with an irregular heartbeat called atrial fibrillation were free of any recurrent atrial arrhythmias or symptoms. By comparison, only 17 percent of those treated with drugs were arrhythmia-free. Results were so convincing the trial was halted early. The ablation group also scored significantly higher on a quality-of-life scale. The study included 167 patients at 19 centers, including 15 centers in the United States. Lead researcher Dr. David Wilber presented results at Heart Rhythm 2009, the Society"s 30th Annual Scientific Sessions. Wilber is director of the Cardiovascular Institute at Loyola University Stritch School of Medicine in Maywood, Il. Atrial fibrillation, often called A-Fib, is the most common form of irregular heartbeat. Electrical signals, which regulate the heartbeat, become erratic. Instead of beating regularly, the upper chambers of the heart quiver. Not all the blood gets pumped out, so clots can form. Atrial fibrillation can lead to strokes and heart failure. A-Fib patient Robin Drabant, 35, of Hanover Park, Il., said the condition once "made me feel like I was 90 years old with a failing heart." She was on a maximum dose of an A-Fib medication, which caused fatigue. Despite the drug, she still had episodes almost every day, lasting from 10 seconds to an hour or longer. "I would lose my breath and could feel my heart racing and fluttering," she said. Wilber performed a catheter ablation on Drabant in May, 2008, and she no longer has A-Fib episodes. "I had great results," she said. A-Fib symptoms include heart palpitations, dizziness, fatigue, shortness of breath and fainting. "A lot of people are disabled," Wilber said. "They have no energy. They can"t work. They have a very poor quality of life." More than 2 million Americans have atrial fibrillation, and there are about 160,000 new cases each year. The number is increasing, due in part to the aging population and the obesity epidemic. Drugs such as beta blockers and calcium channel blockers can slow the heart rate during an A-Fib episode. Other drugs such as flecainide and propafenone can help maintain a normal rhythm. When drugs don"t work or produce unacceptable side effects, alternative treatments include a pacemaker, surgery and catheter ablation. In the ablation procedure, an electrophysiologist destroys small areas of heart tissue that are responsible for the erratic electrical signals. A catheter (thin flexible tube) is guided through blood vessels to the heart. The tip of the catheter delivers radiofrequency energy that heats and destroys tissue. Possible adverse effects include irritation of the lining of the heart, fluid in the lungs or around the heart, bleeding, clots and stroke. In the study, 106 patients with frequent episodes of atrial fibrillation were randomly assigned to undergo ablation and 61 similar patients were randomly assigned to receive drug therapy. All patients had experienced at least three episodes of atrial fibrillation during the previous six months and had failed at least one attempt to control the rhythm with drugs. The study was funded by Biosense Webster, which makes the ThermoCool catheter used in the trial. Wilber is a consultant to the company. The study was the largest to date to compare ablation to drug therapy for atrial fibrillation. Earlier studies involved single centers and smaller sample sizes, Wilber said. An additional study called CABANA is designed to determine whether ablation patients live longer than patients receiving medication. Researchers will follow about 3,000 patients for three years. Heart Rhythm 2009 May 13-16 at the Boston Exhibition and Convention Center. Jim Ritter Loyola University Health System


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):